(Sharecast News) - Avacta Therapeutics said on Wednesday that new data from the phase 1b cohort of its ongoing trial of faridoxorubicin, also known as AVA6000, showed clinically meaningful tumour shrinkage in patients with salivary gland cancer, reinforcing results previously reported from the phase 1a stage of the study.

The...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE